Anifrolumab Treatment Leads to Rapid Reduction in Urinary Biomarkers of Intrarenal Inflammation in Lupus Nephritis: Results from the Phase 2 TULIP-LN Trial - PubMed
3 months ago
- #anifrolumab
- #biomarkers
- #lupus nephritis
- Anifrolumab, an approved SLE treatment, was studied in the TULIP-LN phase 2 trial for lupus nephritis (LN).
- The trial showed anifrolumab significantly reduced urinary biomarkers CD163 and MCP-1 by Week 12 compared to placebo.
- Standard therapy alone eventually reduced biomarker levels by Week 48, but more slowly than anifrolumab.
- Anifrolumab was superior to placebo in reducing proteomic inflammatory signatures, regardless of responder status.
- The findings suggest anifrolumab may accelerate resolution of intrarenal inflammation, potentially preventing kidney damage.